ACAD
ACADIA Pharmaceuticals Inc.
ACAD's fundamentals are mixed, but it looks cheap: trading at 8.6x earnings, about half its usual 16x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ACAD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
ACAD's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ACAD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.6x | $18.14 | — |
| Cheap | 9.8x | $20.70 | +14% |
| Fair | 16x | $33.30 | +84% |
| Forward | 17x | $18.14 | — |
| Expensive | 23x | $47.72 | +163% |
Historical ranges are pointers, not guarantees.
ACAD's PE is in its cheap range at 8.6x. On analysts' estimates for next year's earnings, today's price would be 17x, in its fair range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ACAD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ACAD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ACAD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.05 | -50% |
| Q3 2026 | $2.12 | +37% |
| Q2 2026 | $2.23 | +68% |
| Q1 2026 | $2.21 | +61% |
| Q4 2025 | $2.30 | +69% |
| Q3 2025 | $1.55 | +99% |
| Q2 2025 | $1.33 | +639% |
| Q1 2025 | $1.37 | +$1.38 |
| Q4 2024 | $1.36 | +$1.74 |
ACAD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ACAD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $342.3M | +23% |
| Q2 2026 | $308M | +16% |
| Q1 2026 | $268.1M | +9.7% |
| Q4 2025 | $284M | +9.4% |
| Q3 2025 | $278.6M | +11% |
| Q2 2025 | $264.6M | +9.3% |
| Q1 2025 | $244.3M | +19% |
| Q4 2024 | $259.6M | +12% |
ACAD's revenue has grown year over year for 16 quarters in a row: $342M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +8.1 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | -1.7% | -9.6 points |
| Q4 2025 | 6.1% | -53 points |
| Q3 2025 | 13% | +0.2 points |
| Q2 2025 | 12% | -0.3 points |
| Q1 2025 | 7.9% | +0.5 points |
| Q4 2024 | 59% | +44 points |
ACAD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ACAD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ACAD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | -86% |
| Q1 2026 | $28.8M | +42% |
| Q4 2025 | -$52.7M | -232% |
| Q1 2025 | $20.3M | -30% |
| Q4 2024 | $39.9M | -53% |
| Q2 2024 | $25M | +205% |
| Q1 2024 | $29.1M | +$47M |
| Q4 2023 | $85.4M | +$109.2M |
ACAD has burned cash in most quarters: $82M over the past year, down 48% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ACAD on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACAD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +2.6M shares |
| 1 year | +2.8% | +4.8M shares |
| 3 years | +8.8% | +14.2M shares |
| 5 years | +13% | +20.1M shares |
ACAD has 175M diluted shares, up 2.8% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ACAD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ACAD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.4x | Net Cash |
| Q2 2026 | -3.9x | Net Cash |
| Q1 2026 | -3.0x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
ACAD has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ACAD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 18.4 | Oversold |
ACAD's weekly RSI is 35 (neutral) and its Stochastic is 18 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ACAD PE vs Healthcare Sector
| Metric | ACAD | Sector median | Relative |
|---|---|---|---|
| PE | 8.6x | 26x | 67% below |
| PE % | 0 | 29 | 29 pts below |
ACAD is trading at 8.6x earnings, a 67% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ACAD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.9 | 8.8% below |
| 20 week MA | $24.4 | 26% below |
| 50 week MA | $23.8 | 24% below |
| 100 week MA | $22.2 | 18% below |
| 200 week MA | $21.6 | 16% below |
ACAD is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ACAD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $55.0 | +25% |
| 2021 | $55.0 | $24.3 | -56% |
| 2022 | $24.3 | $15.5 | -36% |
| 2023 | $15.5 | $31.3 | +102% |
| 2024 | $31.3 | $17.0 | -46% |
| 2025 | $17.0 | $27.6 | +63% |
| 2026 YTD | $27.6 | $18.1 | -34% |
ACAD has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.